Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia

Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia

In pediatric acute myeloid leukemia (AML), fusions involving lysine methyltransferase 2A (KMT2A) are considered hallmarks of aggressive AML, for whom the development of targeted specific therapeutic agents to ameliorate classic chemotherapy and obtain a complete eradication of disease is urgent. In...

Full description

Bibliographic Details
Main Authors: Claudia Tregnago, Maddalena Benetton, Ambra Da Ros, Giulia Borella, Giorgia Longo, Katia Polato, Samuela Francescato, Alessandra Biffi, Martina Pigazzi
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Pharmacology
Subjects:
AML
KMT2A
venetoclax
synergy
targeted drugs
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.820191/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.820191/full

Similar Items